A Multicenter Prospective Study Evaluating Efficacy and Safety of a Single-incision Sling Procedure for Stress Urinary Incontinence |
| |
Authors: | Ty Erickson Jan-Paul Roovers Edward Gheiler Mitesh Parekh Mohamad Parva Craig Hanson Rebecca McCrery Le Mai Tu |
| |
Affiliation: | 1. Department of Gynaecology, Rosemark Women Care Specialists, Idaho Falls, Idaho (Dr. Erickson);2. Department of Gynaecology, Amsterdam UMC, Amsterdam, Netherlands (Dr. Roovers);3. Department of Gynaecology, Nova Southeastern University/Urological Research Network LLC, Hialeah, Florida (Dr. Gheiler);4. Department of Gynaecology, Genesis Healthcare, Zanesville, Ohio (Dr. Parekh);5. Department of Gynaecology, The Group for Women, Tidewater Clinical Research, Norfolk, Virginia (Dr. Parva);6. Department of Gynaecology, Women''s Health Advantage, Fort Wayne, Indiana (Dr. Hanson);7. Department of Gynaecology, Adult and Pediatric Urology and Urogynecology, Omaha, Nebraska (Dr. McCrery);8. Department of Surgery, Division of Urology, Hospital Center, University of Sherbrooke, Sherbrooke, Quebec, Canada (Dr. Tu) |
| |
Abstract: | Study ObjectiveThe aim of the Altis 522 study was to compare the safety and efficacy of the Altis Single-Incision Sling System (SIS) (Coloplast, Minneapolis, MN) with standard midurethral transobturator and/or retropubic slings through 36 months. In this report, we present data through 12 months of follow-up.DesignPostmarket, prospective, multicenter, nonrandomized cohort design.SettingThe study was performed at 23 hospitals in the United States and Canada.PatientsAdult female patients with stress urinary incontinence (SUI) clinically indicated for an incontinence sling were treated (n = 355).InterventionsAltis SIS was compared with any Food and Drug Administration–cleared transobturator or retropubic sling.Measurements and Main ResultsCollected measures included device- and/or procedure-related serious adverse events, relevant nonserious and all adverse events, and revision surgery. Objective efficacy measures included 24-hour pad weight, dryness (defined as pad weight ≤4.0 g), and cough stress test. Subjective outcome measures included patient global impression of improvement, urogenital distress inventory, Incontinence Impact Questionnaire–Short Form, Surgical Satisfaction Questionnaire, and visual analog scale for pain.At 12 months, 24-hour pad weight success (≥50% reduction), negative cough stress test, patient global impression of improvement, urogenital distress inventory, and Incontinence Impact Questionnaire–Short Form appeared similar between groups. Through 12 months, 2 subjects in the Altis group and 3 subjects in the comparator group experienced a serious device- and/or procedure-related adverse event. In the Altis group, 1 subject (0.5%) experienced a device revision, and 1 subject (0.5%) had the device explanted. In the comparator group, 7 subjects (4.1%) experienced a device revision, and 1 device (0.6%) was explanted before the 12-month visit. The occurrence of relevant nonserious procedure and/or device-related adverse events was similar between groups.ConclusionAt 12-months follow-up, safety and efficacy appeared similar between Altis SIS and standard transobturator and retropubic midurethral slings. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|